AnGes, Inc.
Notice on the Acquisition and Cancellation of the 46th Stock Acquisition Rights and Others
Acquisition and cancellation of the 46th stock acquisition rights. Completion of redemption of the 2nd unsecured bond as of September 1. Planned fundraising of approximately 8,500 million yen through third-party allotment of the 47th and 48th stock acquisition rights and issuance of stock acquisition rights with warrants. Planned business alliance with GP Fund and Growth Partners to balance capital policy and business expansion.
Key Figures
- 47th stock acquisition rights total: 796,337 units
- 48th stock acquisition rights total: 573,658 units
- Total potential shares: 136,999,500 shares (upon exercise of stock acquisition rights) + 45,977,011 shares (upon conversion)
- Dilution rate: 45.88%
- Total fundraising (expected): 8,500 million yen (total paid-in amount and exercise-time total expected)
AI要約
Overview of Capital Policy
This time AnGes executed the acquisition and cancellation of the 46th stock acquisition rights with Cantor Fitzgerald Europe as the allottees. In addition, it will terminate the unsecured private placement facility and redeem the 2nd unsecured bonds on September 1. In the future, it plans to issue third-party allotments for the 47th and 48th stock acquisition rights together with stock acquisition rights with warrants, aiming to raise approximately 8,500 million yen. A business alliance with GP Fund and Growth Partners will be established to pursue both capital policy and business expansion.
Outlook and Risks
The allocation scheme is designed to enhance funding probability, and the exercise price may be adjusted according to share price movements. While there is potential for dilution, the aim is to secure funds early and improve corporate value over the medium to long term. Use of funds is expected for U.S. development costs of HGF gene therapy, relocation costs for EmendoBio facilities, expansion of contract testing with ACRL, and working capital. Note that procedures such as an extraordinary general meeting of shareholders may be required.
AnGes株式会社
Company overview · Stock price · Financial data · All IR
